 Bausch Health Companies BHC , Financial received a devastating body blow on Thursday when a U.S. federal court judge invalidated some key patents on its largest product Xifaxan for the treatment of irritable bowel syndrome. The judgement was oral, and full details are not available yet, but Bauschs stock plummeted more than 50 following the news before trading was halted. 